Systemic barriers block methamphetamine dependency treatment: Mirtazapine’s limited efficacy reveals gaps in harm reduction and structural healthcare inequities
Original framing: “This common antidepressant helps people cut back on methamphetamine – new study” — The Conversation - Global
In Portugal, decriminalization of all drugs in 2001 shifted the focus from punishment to health, reducing HIV transmission and drug-related deaths by over 80%. Indigenous communities in Canada and Australia have successfully integrated traditional healing with Western medicine in addiction treatment, though these models are rarely funded or studied. In Vietnam, methamphetamine use is addressed through family and community networks, with lower relapse rates than in Western clinics that isolate individuals. These cross-cultural examples demonstrate that recovery is not solely a medical issue but a social and spiritual one.
The study’s focus on mirtazapine as a solution to methamphetamine dependency exemplifies how Western biomedicine frames complex social crises as technical problems solvable by pharmaceuticals.
This approach obscures the historical roots of addiction—rooted in colonial violence, racial capitalism, and the erosion of communal support systems—while privileging market-driven interventions over holistic, community-led care. Cross-cultural evidence demonstrates that recovery thrives in contexts where dignity, connection, and cultural identity are prioritized, as seen in Portugal’s decriminalization model or Māori-led healing programs. The systemic crisis of methamphetamine dependency cannot be resolved by a single drug but requires dismantling the structural inequities that fuel it, from punitive drug policies to the lack of affordable housing and mental healthcare. True progress demands a paradigm shift: from criminalization to compassion, from isolation to community, and from pharmaceutical quick-fixes to long-term, people-centered solutions.